Home › Metastatic Cancer › Massachusetts
Metastatic Cancer clinical trials in Massachusetts
63 studies for Metastatic Cancer are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Nov 12, 2026 · NCT05372640Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04585958A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07458347Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- and 1 more
RecruitingPhase 2
All ages · All sexes · Updated Nov 12, 2026 · NCT05564377Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT05372614A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Nov 6, 2026 · NCT05384626A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital (MG), Boston
RecruitingPhase 1
Ages 18 to 99 · All sexes · Updated Nov 6, 2026 · NCT06983743A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Nov 5, 2026 · NCT06586957A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07029399A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Mass General Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- University of Massachusetts Medical School, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07174336A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06465069A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Massachusetts Chan Medical School, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07213804A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07114601A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Boston Medical Center, Boston
- Lahey Hospital & Medical Center, Burlington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06119581FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05614739A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Nov 3, 2026 · NCT04802759Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06943755Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06127407A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Boston
- Research Site, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06835569Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
- Massachusetts General Hospital, Boston
Recruiting
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07364474A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT04657068Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06311214A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06521554A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT06244771Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT07137416AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Boston
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Oct 16, 2026 · NCT07038343Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- Mass General Cancer Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06915753A Study of ASP3082 in Adults With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT05382559Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Massachusetts General Hospital Cancer Center, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06757634Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07227415Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
- Dana-Farber Brigham Cancer Center - Foxborough, Foxborough
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07222800A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Massachusetts General Hospital, Boston
- University of Massachusetts Medical School, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT07218380FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT05919264BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- Avenzo Therapeutics Recruiting Site, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07193511The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06625775A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Dana Farber Cancer Institute., Boston
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Mass General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 24, 2026 · NCT05118789Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06302621From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.